Cholic Acid

Brand names: Cholbam · Active ingredient: Cholic Acid

In short: CHOLBAM is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs). CHOLBAM is indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or com

Forms & strengthsCHOLBAM is available in two capsule strengths: •50 mg capsule: Size number 2 Swedish orange capsule with cap imprinted with “50mg” and body imprinted with “ASK001”. The capsules contain a white to off-white powder. …
LabelMirum Pharmaceuticals Inc.
Label updatedJan 30, 2026

What is Cholic Acid used for?

CHOLBAM is indicated for the treatment of bile acid synthesis disorders due to single enzyme defects (SEDs).

CHOLBAM is indicated for adjunctive treatment of peroxisomal disorders (PDs) including Zellweger spectrum disorders in patients who exhibit manifestations of liver disease, steatorrhea or complications from decreased fat-soluble vitamin absorption.

The safety and effectiveness of CHOLBAM on extrahepatic manifestations of bile acid synthesis disorders due to SEDs or PDs including Zellweger spectrum disorders have not been established.

Cholic Acid dosage

The recommended dosage of CHOLBAM is 10 to 15 mg/kg administered orally once daily or in two divided doses, in pediatric patients and adults.

Table 1 and Table 2 show the number of capsules that should be administered daily to approximate a dosage of 10 mg/kg/day and 15 mg/kg/day, respectively, using the available 50 mg and 250 mg capsules alone or in combination.

10 mg/kg/day Dosage

Body Weight (kg) | Number of 50 mg capsules | Number of 250 mg capsules

4 to 6 | 1 | 0

7 to 10 | 2 | 0

11 to 15 | 3 | 0

16 to 20 | 4 | 0

21 to 25 | 0 | 1

26 to 30 | 1 | 1

31 to 35 | 2 | 1

36 to 40 | 3 | 1

41 to 45 | 4 | 1

46 to 50 | 0 | 2

51 to 55 | 1 | 2

56 to 60 | 2 | 2

61 to 65 | 3 | 2

66 to 70 | 4 | 2

71 to 75 | 0 | 3

76 to 80 | 1 | 3

15 mg/kg/day Dosage

Body Weight (kg) | Number of50 mg capsules | Number of 250 mg capsules

4 to 5 | 1 | 0

6 to 9 | 2 | 0

10 to 13 | 3 | 0

14 to 16 | 4 | 0

17 to 19 | 0 | 1

20 to 23 | 1 | 1

24 to 26 | 2 | 1

27 to 29 | 3 | 1

30 to 33 | 4 | 1

34 to 36 | 0 | 2

37 to 39 | 1 | 2

40 to 43 | 2 | 2

44 to 46 | 3 | 2

47 to 49 | 4 | 2

50 to 53 | 0 | 3

54 to 56 | 1 | 3

57 to 59 | 2 | 3

60 to 63 | 3 | 3

64 to 66 | 4 | 3

67 to 69 | 0 | 4

70 to 73 | 1 | 4

74 to 76 | 2 | 4

77 to 79 | 3 | 4

80 | 4 | 4

Patients with newly diagnosed, or a family history of, familial hypertriglyceridemia may have poor absorption of CHOLBAM from the intestine and require a 10% increase in the recommended dosage to account for losses due to malabsorption. The recommended dosage of CHOLBAM in patients with concomitant familial hypertriglyceridemia is 11 to 17 mg/kg orally once daily, or in two divided doses. Adequacy of the dosage regimen can be determined by monitoring the patient’s clinical response including steatorrhea and laboratory values of serum transaminases, bilirubin, and prothrombin time/international normalized ratio (PT/INR).

Treatment with CHOLBAM should be initiated and monitored by an experienced hepatologist or pediatric gastroenterologist.

Monitor serum aspartate aminotransferase (AST), serum alanine aminotransferase (ALT), serum gamma glutamyltransferase (GGT), alkaline phosphatase, bilirubin, and INR every month for the first 3 months, every 3 months for the next 9 months, every 6 months during the subsequent three years, and annually thereafter. Monitor more frequently during periods of rapid growth, concomitant disease, and pregnancy. Administer the lowest dose of CHOLBAM that effectively maintains liver function .

Discontinue treatment with CHOLBAM if liver function does not improve within 3 months of the start of treatment or if complete biliary obstruction develops.

Discontinue treatment with CHOLBAM at any time if there are persistent clinical or laboratory indicators of worsening liver function or cholestasis . …

How to take Cholic Acid — instructions & advice from the label

Exacerbation of Liver Impairment

•Advise patients that they will need to undergo laboratory testing periodically while on treatment to assess liver function.

•Advise patients that CHOLBAM may worsen liver impairment and that they should immediately report to their health care provider any symptoms associated with liver impairment (e.g., yellowing of the skin or the whites of the eye, dark or tea-colored urine, pain on the right side of stomach, bleeding or bruising occurs more easily than normal, or increased lethargy)

Administration

Advise patients:

•to take CHOLBAM with food.

•to take CHOLBAM at least one hour before or 4 to 6 hours after taking a bile acid binding resin or an aluminum-based antacid.

•not to crush or chew the capsules.

•for infants and children who cannot swallow capsules, the capsules can be opened and the contents mixed with either infant formula or expressed breast milk (for younger children), or soft food such as mashed potatoes or apple puree (for older children and adults) in order to mask any unpleasant taste:

1.Hold the capsule over the prepared liquid/food, gently twist open, and allow the contents to fall into the liquid/food. …

Warnings & precautions

Do not take this medicine if: None.

In clinical trials, evidence of liver impairment was present before treatment with CHOLBAM in approximately 86% (44/51) of patients with bile acid synthesis disorders due to SEDs and in approximately 50% (14/28) of patients with PDs including Zellweger spectrum disorders. Five of the patients (3 SED and 2 PD) with liver impairment at baseline experienced worsening serum transaminases, elevated bilirubin values, or worsening cholestasis on liver biopsy following treatment. Five additional patients (2 SED and 3 PD) who did not have baseline cholestasis experienced exacerbation of their liver disease while on treatment. In patients with cirrhosis, cases of severe hepatotoxicity have also been observed following postmarket use of CHOLBAM. Exacerbation of liver impairment by CHOLBAM in these patients cannot be ruled out.

Six patients with SEDs underwent liver transplant, including four patients diagnosed with AKR1D1 deficiency, one with 3β-HSD deficiency, and one with CYP7A1 deficiency.

Concurrent elevations of serum GGT and ALT may indicate CHOLBAM overdose .

Monitor liver function and discontinue CHOLBAM in patients who develop worsening of liver function while on treatment. Discontinue treatment with CHOLBAM at any time if there are clinical or laboratory indicators of worsening liver function or cholestasis .

Cholic Acid side effects

The following clinically significant adverse reaction is described elsewhere in the labeling:

•Exacerbation of Liver Impairment

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Clinical safety experience with CHOLBAM consists of:

•Trial 1: a non-randomized, open-label, single-arm trial of 50 patients with bile acid synthesis disorders due to SEDs and 29 patients with PDs including Zellweger spectrum disorders. Safety data are available over the 18 years of the trial.

•Trial 2: an extension trial of 12 new patients (10 SED and 2 PD) along with 31 (21 SED and 10 PD) patients who rolled over from Trial 1. Safety data are available for 3 years and 11 months of treatment.

Adverse events were not collected systematically in either of these trials. Most patients received an oral dose of 10 to 15 mg/kg/day of CHOLBAM.

Deaths

In Trial 1, among the 50 patients with SEDs, 5 patients aged 1 year or less died, which included three patients originally diagnosed with AKR1D1 deficiency, one with 3β-HSD deficiency and one with CYP7A1 deficiency. The cause of death was attributed to progression of underlying liver disease in every patient.

Of 29 patients in Trial 1 with PDs including Zellweger spectrum disorders, 12 patients between the ages of 7 months and 2.5 years died. …

Drug interactions

Drug interactions with CHOLBAM mainly relate to agents capable of interrupting the enterohepatic circulation of bile acids.

Inhibitors of Bile Acid Transporters

Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP) such as cyclosporine. Concomitant medications that inhibit canalicular membrane bile acid transporters such as the BSEP may exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is deemed necessary, monitoring of serum transaminases and bilirubin is recommended.

Bile Acid Binding Resins

Bile acid binding resins such as cholestyramine, colestipol, or colesevelam adsorb and reduce bile acid absorption and may reduce the efficacy of CHOLBAM. Take CHOLBAM at least 1 hour before or 4 to 6 hours (or at as great an interval as possible) after a bile acid binding resin .

Aluminum-Based Antacids

Aluminum-based antacids have been shown to adsorb bile acids in vitro and can reduce the availability of CHOLBAM. Take CHOLBAM at least 1 hour before or 4 to 6 hours (or at as great an interval as possible) after an aluminum-based antacid .

About this medicine

Cholic acid is a bile acid. The chemical formula is C24H40O5, the molecular weight is 408.57 and the chemical structure is:

Cholic acid is a white to off-white powder. It is practically insoluble in water and in 0.1 M HCl at 20°C and is sparingly soluble in 0.1 M NaOH at 20°C. It is soluble in glacial acetic acid, alcohols, and acetone. A saturated solution in water at 20°C has a pH of 4.4.

CHOLBAM capsules contain 50 mg or 250 mg of cholic acid as the active ingredient in size 2 Swedish orange or size 0 white opaque gelatin capsules, respectively. Inactive ingredients in CHOLBAM include crospovidone, magnesium stearate, and silicified microcrystalline cellulose.

The size 2 capsule shells contain gelatin, red iron oxide and titanium dioxide, and the size 0 capsule shells contain gelatin and titanium dioxide. CHOLBAM is administered orally.

How it works: Cholic acid is a primary bile acid synthesized from cholesterol in the liver. …

Disclaimer: This page is for general information only and is not medical advice. It is a condensed summary of the official FDA-approved label — it does not replace the full prescribing information or the advice of your doctor or pharmacist. Always follow your prescriber's instructions and read the medication guide that comes with your medicine.

Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID 5c6e4c9d-b85e-493f-9420-ab2fd0ff3723. Read the full official label on DailyMed.